These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 23430138)
41. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. Knorr B; Larson P; Nguyen HH; Holland S; Reiss TF; Chervinsky P; Blake K; van Nispen CH; Noonan G; Freeman A; Haesen R; Michiels N; Rogers JD; Amin RD; Zhao J; Xu X; Seidenberg BC; Gertz BJ; Spielberg S J Clin Pharmacol; 1999 Aug; 39(8):786-93. PubMed ID: 10434229 [TBL] [Abstract][Full Text] [Related]
42. Evaluating the effect of coating equipment on tablet film quality using terahertz pulsed imaging. Haaser M; Naelapää K; Gordon KC; Pepper M; Rantanen J; Strachan CJ; Taday PF; Zeitler JA; Rades T Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1095-102. PubMed ID: 23563103 [TBL] [Abstract][Full Text] [Related]
43. Evaluation of recent advances in continuous film coating processes. Cunningham C; Hansell J; Nuneviller F; Rajabi-Siahboomi AR Drug Dev Ind Pharm; 2010 Feb; 36(2):227-33. PubMed ID: 19954403 [TBL] [Abstract][Full Text] [Related]
44. Effect of xanthan gum-based food thickeners on the dissolution profile of fluoroquinolones oral formulations. Takahashi N; Fujita Y; Takahashi N; Nakamura A; Harada T J Pharm Health Care Sci; 2020 Nov; 6(1):25. PubMed ID: 33292643 [TBL] [Abstract][Full Text] [Related]
45. An automated method for the determination of montelukast in human plasma using dual-column HPLC analysis and peak height summation of the parent compound and its photodegradation product. Smith GA; Rawls CM; Kunka RL Pharm Res; 2004 Sep; 21(9):1539-44. PubMed ID: 15497676 [TBL] [Abstract][Full Text] [Related]
46. Interchangeability and comparative effectiveness between generic and brand montelukast immediate release tablets after a single oral administration in healthy volunteers. Zaid AN; Mousa A; Ghazal N; Bustami R Clin Transl Allergy; 2015; 5():37. PubMed ID: 26561521 [TBL] [Abstract][Full Text] [Related]
47. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers. Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813 [TBL] [Abstract][Full Text] [Related]
48. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Lake OA; Olling M; Barends DM Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323 [TBL] [Abstract][Full Text] [Related]
49. Development and evaluation of a time-specific pulsatile-release tablet of aceclofenac: a solution for morning pain in rheumatoid arthritis. Qureshi J; Ahuja A; Baboota S; Chutani K; Jain S; Ali J Methods Find Exp Clin Pharmacol; 2009; 31(1):15-23. PubMed ID: 19357794 [TBL] [Abstract][Full Text] [Related]
50. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies. Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183 [TBL] [Abstract][Full Text] [Related]
51. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations. Martir J; Flanagan T; Mann J; Fotaki N AAPS PharmSciTech; 2020 Oct; 21(7):287. PubMed ID: 33063245 [TBL] [Abstract][Full Text] [Related]
52. Release characteristics and in vitro-in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling. Lin HL; Lin SY; Lin YK; Ho HO; Lo YW; Sheu MT Eur J Pharm Biopharm; 2008 Sep; 70(1):289-301. PubMed ID: 18539015 [TBL] [Abstract][Full Text] [Related]
53. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug. Avramoff A; Domb AJ Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers. Kranz H; Gutsche S Int J Pharm; 2009 Oct; 380(1-2):112-9. PubMed ID: 19632313 [TBL] [Abstract][Full Text] [Related]
55. Simultaneous estimation of Montelukast sodium and Bambuterol hydrochloride in tablets by spectrophotometry. Nanda RK; Pangarkar VB; Thomas AB; Kothapalli LP; Pawar AA Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):29-33. PubMed ID: 19957541 [TBL] [Abstract][Full Text] [Related]
56. A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. Vemula SK AAPS PharmSciTech; 2015 Dec; 16(6):1465-73. PubMed ID: 26017285 [TBL] [Abstract][Full Text] [Related]
57. Montelukast microsuspension with hypromellose for improved stability and oral absorption. Lee HR; Park HJ; Park JS; Park DW; Ho MJ; Kim DY; Lee HC; Kim EJ; Song WH; Park JS; Choi YS; Kang MJ Int J Biol Macromol; 2021 Jul; 183():1732-1742. PubMed ID: 34051251 [TBL] [Abstract][Full Text] [Related]
58. Comparative static curing versus dynamic curing on tablet coating structures. Gendre C; Genty M; Fayard B; Tfayli A; Boiret M; Lecoq O; Baron M; Chaminade P; Péan JM Int J Pharm; 2013 Sep; 453(2):448-53. PubMed ID: 23792043 [TBL] [Abstract][Full Text] [Related]
59. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Okumu A; DiMaso M; Löbenberg R Pharm Res; 2008 Dec; 25(12):2778-85. PubMed ID: 18560996 [TBL] [Abstract][Full Text] [Related]
60. Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. He W; Fan LF; Du Q; Xiang B; Li CL; Bai M; Chang YZ; Cao DY Chem Pharm Bull (Tokyo); 2009 Feb; 57(2):122-8. PubMed ID: 19182399 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]